Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Financial Statements Details - Intangible Assets, Net (Details)

v3.25.2
Condensed Consolidated Financial Statements Details - Intangible Assets, Net (Details) - USD ($)
$ in Thousands
Jun. 30, 2025
Dec. 31, 2024
Intangible assets, net    
Cost $ 46,839 $ 26,115
Accumulated Amortization 1,405 206
Net Carrying Value 45,434 25,909
Projected amortization expense for the next five years    
2025 (excluding the six months ended June 30, 2025) 1,757  
2026 3,513  
2027 3,513  
2028 3,513  
2029 3,513  
Thereafter 29,625  
Total $ 45,434  
Minimum    
Intangible assets, net    
Estimated remaining life of intangible assets 11 years 4 months 24 days  
Maximum    
Intangible assets, net    
Estimated remaining life of intangible assets 15 years 4 months 24 days  
Pulmokine - Seralutinib IP    
Intangible assets, net    
Cost $ 26,115 26,115
Accumulated Amortization 1,294 206
Net Carrying Value 24,821 $ 25,909
BioInvent - Contract-based Intangible Asset    
Intangible assets, net    
Cost 20,724  
Accumulated Amortization 111  
Net Carrying Value $ 20,613